These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16841902)

  • 1. On-chip titration of an anticoagulant argatroban and determination of the clotting time within whole blood or plasma using a plug-based microfluidic system.
    Song H; Li HW; Munson MS; Van Ha TG; Ismagilov RF
    Anal Chem; 2006 Jul; 78(14):4839-49. PubMed ID: 16841902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
    Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
    Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
    He S; Wallèn H; Bark N; Blombäck M
    J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia.
    Guy S; Kitchen S; Hopkins B; Chunara Z; Stephenson-Brown A; van Veen JJ
    Int J Lab Hematol; 2022 Apr; 44(2):399-406. PubMed ID: 34755452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
    Guy S; Kitchen S; Maclean R; Van Veen JJ
    Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).
    Guy S; Kitchen S; Makris M; M Maclean R; Saccullo G; Vanveen JJ
    Clin Appl Thromb Hemost; 2021; 27():10760296211066945. PubMed ID: 34905962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
    Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
    Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.
    Tripodi A; Chantarangkul V; Padovan L; Clerici M; Scalambrino E; Peyvandi F
    J Thromb Thrombolysis; 2020 Apr; 49(3):413-419. PubMed ID: 31728842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Performance evaluation of the STA ECA-II reagent for specific assay of anti-IIa activity of argatroban].
    Genin A
    Ann Biol Clin (Paris); 2021 Dec; 79(6):603-611. PubMed ID: 34961741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
    Francis JL; Hursting MJ
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
    Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
    Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative monitoring of argatroban using plasma-diluted thrombin time.
    Wanat MA; Hart SR; Putney D; Liebl MG; Chandler W
    Ann Pharmacother; 2013 Apr; 47(4):e18. PubMed ID: 23482736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
    Nagashima H
    J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.
    Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
    Thromb Res; 2008; 123(1):159-65. PubMed ID: 18433842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental and clinical results with the thrombin inhibitor Argatroban].
    Breddin HK
    Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GFHT proposals on the practical use of argatroban - With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT).
    Siguret V; Boissier E; De Maistre E; Gouin-Thibault I; James C; Lasne D; Mouton C; Godon A; Nguyen P; Lecompte T;
    Anaesth Crit Care Pain Med; 2021 Dec; 40(6):100963. PubMed ID: 34673303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.